Teva, Lilly and Amgen join battle for new $8bn migraine prevention market
This article was originally published in Scrip
New biologicals targeting the CGRP pathway could prove to be the biggest thing to hit the migraine market since the triptans in the 1990s, mid-stage data presented at the recent American Headache Society meeting in Washington suggest.
You may also be interested in...
Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data
Amgen and Novartis revealed the first set of Phase III data for a CGRP inhibitor in the treatment of episodic migraine, potentially positioning the companies’ biologic erenumab at the head of the drug class.
Amgen Earnings Beat Expectations; Company Pushing Payers On Repatha
Amgen Inc.'s first quarter revenue and earnings beat consensus estimates without a meaningful contribution from sales of the cholesterol-reducing biologic Repatha (evolocumab), but the company is pushing back against payers that are denying reimbursement to appropriate patients.
Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.